Browse > Article
http://dx.doi.org/10.4333/KPS.2003.33.2.085

Improvement of Solubility and Bioavailability of Poorly Water Soluble Piroxicam with L-Arginine Complex  

Hong, Seok-Cheon (R&D center, Korea United Pharm. Inc.)
Yu, Chang-Hun (R&D center, Korea United Pharm. Inc.)
Cho, Dong-Hyun (R&D center, Korea United Pharm. Inc.)
Shin, Hyun-Jong (R&D center, Korea United Pharm. Inc.)
Gil, Young-Sig (R&D center, Korea United Pharm. Inc.)
Publication Information
Journal of Pharmaceutical Investigation / v.33, no.2, 2003 , pp. 85-89 More about this Journal
Abstract
Piroxicam-arginine complex was prepared to improve the solubility and dissolution rate of poorly water-soluble piroxicam. Its formation was identified by infrared spectrophotometry, differential thermal analysis and dissolution rate. Piroxicam complex dispersible tablets, commercial $Feldene^{\circledR}$ dispersible tablets and piroxicam physical mixture hard capsules were prepared to compare dissolution rate in water. Dissolved amounts (%) after 15 mins of piroxicam complex dispersible tablets, commercial $Feldene^{\circledR}$ dispersible tablets and piroxicam physical mixture hard capsules were 98%, 48% and 10%, respectively. The solubility of complex in water was significantly higher than that of piroxicam itself. In vivo, pharmacokinetic parameters were obtained after oral administrations of piroxicam complex and physical mixture at a does of 2 mg to New Zealand White Rabbit. The $C_{max}$ of piroxicam complex was similar to that of piroxicam. However, there were much difference between the two formulations with regard to $T_{max}$ and AUC. The $T_{max}$ of piroxicam alone was 4 hours, but that of piroxicam complex was 0.8 hours. In addition, the AUC of piroxicam complex was 1.38 times greater than that of piroxicam alone.
Keywords
Complex; Dispersible tablet; L-arginine; Piroxicam; Poorly water soluble;
Citations & Related Records
연도 인용수 순위
  • Reference
1 G.S. Khang, J.M. Lee, H.C. Shin, H.B. Lee and J.K. Jeong, Effect of molecular weights and mixture ratios of polyvinylpyrrolidon on the bioavailability of ipriflavone solid dispersion, J. Kor. Pharm. Sci., 30, 235-239 (2000)
2 Y.J. Lee, Y.G. Kim, M.G. Lee, S.J. Chung, M.H. Lee and C.K. Shim, Analysis of bioequivalence study using longtransformed model, Yakhak Hoeji, 44, 308-314 (2000)
3 C.K. Kim and H.J. Shin, Soluble complex formation of rifampicin with arginine, Yakhak Hoeji; 27, 11-19 (1983).
4 J. H. Kim and H.Y Choi, Complexation of piroxicam and tenoxicam with hydroxypropyl-$\beta$-cyclodexrrin, J. Kor. Pharm. Sci., 30, 33-37 (2000).
5 I.J. Oh, J.G. Park, Y.B. Lee and S.C. Shin, Inclusion complex of analgesic and anti-inflammatory agents with cyclodextrins (1): Enhancement of dissolution of ibuprofen by 2-hydroxypropyl-$\beta$-cyclodextrin, J Kar. Pharm. Sci., 23, 11-18 (1993).
6 S.H. Park, C.H. Lee, Y.W. Choi, G.B. Park and J.K. Kim, Bioavailability studies on suspension of inclusion complexes of piroxicam with cyclodextrin, Kar. J. Clin. Pharm., 1, 914 (1991)
7 I.E. Koh and S.C. Shin and I.J. on, Enhancement of dissolution properties of poorly soluble drugs (IV): Micronization of furosemide by recrystallization method, J. Kor. Pharm. Sci., 18, 55-59 (1998).
8 Gerald K.M., AHFS Drug Information, ASHP, Inc.,Wisconsin, U.S.A., pp. 2016-2020 (2002)
9 Karim A, Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of proteinbinding differences on steady-state pharmaco-kinetics. J. Clin. Pharmacol., 37, 267-278 (1997).   DOI   ScienceOn
10 Sean CS, Martindale; The Complete Drug Reference, Pharmaceutical press, London, UK., pp. 79-80 (2002)
11 Y.B. Jun, S.I. Kim and Y.I. Kim, Effect of surfactants on dissolution rate of mefenamic acid capsules, J. Kor. Pharm. Sci., 20, 121-127 (1990).
12 I.B. Koh, Y.B. Lee and S.C. Shin, Enhanced dissolution rates of piroxicam the ground mixture of chitin Or chitosan, Arch. Pharm. Res. 9, 55-61 (1986)   DOI
13 S.S. Jeon, H.R. Cha, Y.J. Park, B.C. Lee and N.D. Kim, Comparison of absorption rate between piroxicam-$\beta$-pcyclodextrin and piroxicam in Korean healthy subjects after a single dose administration, Kor. J. Clin. Pharm., 8, 95-100 (1998)
14 E.S. Park, B.J. Yun and S.C. Chi, Pharmacokinetic and pharmacological evaluation of topical microemulsion preparation containing piroxicam, J. Appl. Pharmacol., 7, 54-58 (1999)
15 T.S. Lee and B.J. Lee, Enhancement of dissolution rate of poorly water-soluble ibuprofen using solid dispersions and inclusion complex, J. Kor. Pharm. Sci., 25, 31-36 (1995)
16 J.H. Moon and I.K. Chun, Enhanced dissolution and permeation of biphenyl dimethyl dicarboxylate using solid dispersions, J. Kar. Pharm. Sci., 29, 227-234 (1999)